Follow Us on Social Media

    award
    Emergency1066 Apollo lifeline1860-500-1066 24/7
    Dr Subhash Wangnoo

    Endocrinologist

    MBBS, FRCP, DM, MD(Medicine)

    31 years experience overall

    Indraprastha Apollo Hospitals, Sarita Vihar, Delhi-mathura Road, New Delhi - 110076. India Ph:011-26925858 011-29871090/1091, Delhi

    Specialities
    Experience
    • Medical Officer University Health Centre, B.H.U. Varanasi, May 1981 To September 1981.  
    • Senior Resident (Registrar) In Endocrinology. IMS, BHU, Varanasi October 1981 To June 1984.
    • Clinical Attaché in Endocrinology, P.G.I, Chandigarh April 1982 To June 1982.
    • Pool Officer in Endocrinology, IMS BHU, Varanasi, March 1984 To July 1984.
    • Lecturer And Head, Department Of Endocrinology, Sher-I-Kashmir Institute Of Medical Sciences, Srinagar Kashmir July 1984 To July 1988
    • Associate Professor and Head, Department Of Endocrinology, S.K.I.M.S, Srinagar, Kashmir July 1988 To March 1990
    • Honorary Senior Consultant Endocrinologist, Narinder Mohan Hospital, Mohan Nagar Ghaziabad, April 1990 To January 1992
    • Senior Consultant Endocrinologist at King Khalid Hospital, Saudi Arabia (Ministry Of Health), February 1992 To December 1994.
    • Working in Apollo Hospitals since last Assignment
    Members ship
    • Endocrine Society, USA
    • American Diabetes Association
    • Association of American College of Endocrinology
    • Royal College of Physicians of London, UK
    • European Association for Study of Diabetes
    • Diabetes Technology and Therapeutics, USA  
    • International Diabetes Federation 8. Association of Physicians of India
    • Endocrine Society, India
    • Research Society for Study of Diabetes in India
    • Indian Thyroid Society
    • South Asian Association for Regional Co-operation Diabetes Society
    • Indian Menopause Society
    • Diabetes India
    Certifications
    • Honorary fellowship of the royal college of Physician on London(FRCP)in2011.            
    • Invited faculty of various national and international conferences.         
    • Memberof various advisory boards and National And International Academic Guideline forming bodies.  
    • Instrumental in estabilishing the Department of Endocrinology, Diabetes and Metboloic at sher-I-Kashmir Institute of  Medical Sciences,Srinagar,J&K.              
    • Estabilished and currently heading the Apoolo Centre For Obesity, Diabetes and endocinology(ACODE).             
    • Actively involved in teaching and training of DNB Endocrinology students for more than 8 years, the only amongest of Apollo group of hospital having DNB Endocrinology program.
    • Formely honoary endocrinologist to the president of India.                                
    • Wangnoo SK. Initiating insulin therapy in children and adolescents with type I diabetes mellitus. Indian J Endocrinol  Meab.2015 Apr;19(suppl I):S68-70.       
    • Jindal R,Siddiqui MA, Gupta N, Wangnoo SK. Prevalence of glucose intolerance at 6 weeks postpartum in Indian women with gestational diabetes mellitus, Diabetes Metab Syndr.2015 Jul-Sep;9(3):143-6. 
    • Tandon N, Kalra S, Balhara YP, Baruah MP, Chadha M, chandalia HB, Chowdhury S, Jothydev K, Kumar PK, V MS, Mithal A, Modi S, Pitale S, Sahay R, Shukla R, Sundram A, Unnikrishnan AG, Wangnoo SK. Forum for Injection Technique(FIT), India: The Indian  recommendations 2.0, for best practice in Insulin Injection Technique, 2015. Indian K Endocrinol Metab.2015 May-Jun;19(3):317-31.                 
    • Wangnoo SK, Chowdhury S, Rao PV. Treating to target in type 2 diabetes: the BEGIN trial programme. J Assoc Physicians India. 2014 Jan;62(I Suppl):21-6.     
    • Mohan V, Shah SN, Joshi SR, Seshiah V, Sahay BK, Banerjee S, Wangnoo SK, Kumar A, Kalra S, Unnilrishnan AG, Sharma SK, Rao PV, Akhtar S, Shety RV, Das AK; DiabCare India 2011 Study Group. Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study. Indian J Endocrinol Metab. 2014 May:m18(3):370-8.                  
    • Kesavadev J, Sadikot S, Wangnoo S, Kannampilly J, Saboo B, Aravind SR, Kalra S, Makkar BM, Maji D, Saikia M, Anjana RM, Rajput R, Singh SK, Shah S, Dhruv U, Vishwanathan V. Consensus guidelines for glycemic monitoring in  type I/type 2 and GDM. Diabetes Metab syndr.2014Jul-Sep;8(3):187-95.                 
    • Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal  S, Sharma SK. Treat-to-target trials in diabetes. Indian J Endocrinol Metab.2014Mar;18(2):166-74.  
    • Wangnoo SK, Ghosal S, Akhtar S, Shetty R, Tripathi S. Wangnoo SK, Ghosal S, Akhtar S, Shetty R, Tripathi S. Clinical experience of switching from glargine or neutal protamine hagedorn insulin to insulin detemir in type 2 diabetes:Observations from the Indian cohort in the AI chieve study. Indian J Endocrinol Metab, 2014 Sep;18(5):715-20.                
    • Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes. Indian J Endocinol Metab.2014 Mar;18(2):166-74.                 
    • Radhika Jindal, Ayesha Ahmad, Mohammad Asim Siddiqui, Inderpal Singh Kochar, Subhash Kumar Wangnoo. Novel mutation .597_598dup in exon 5 of ABCC8 gene causing congenital hyperinsulinism. Diabetes Metb syndr.2014 Jan-Mar;8(1):45-7.
    • Wangnoo SK, Bader G, Gawai A, Singh S. Effectiveness and Tolerability of Vildagliptin in Indian Patients with Type 2 Diabetes Mellitus: Results From Edge-A Renal-World Obervational Study IJCP.2013;24(6):537-42.      
    • Jindal R, gupta N, Siddiqui MA, Wangnoo SK, Post-Prandial Hyperglycemia.JIACM.2013;14(3-4);242-246. 
    • Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Goke R, Marquez Rodriguez E, Nilson PM, Pagkalos E, Penfornia A, Schaper NC, Wangnoo SK, Kothny W, Bader G. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin pract.2013 oct; 67(10):947-56.
    • Wangnoo SK, Maji D, Das AK, Rao PV, Moses A, Sethi B, Unnikrishnan AG, Kalra S, Balaji V, Bantwal G, Kesavadev J, Jain SM, Dharmalingam M. Barries and solutions to diabetes management: An Indian perspective. Indian J Endocinol Metab.2013 Jul;17(4):594-601.               
    • Niti Agarwal, SK Wangnoo, Asim Siddiqui, Mukul Gupta. primary thyroid Lymphoma: A Series of Two Cases and Review of Literature. JAPI 2013;(61)496-498.
    • Gokulnath, Sahay M, Kalra S, Vishwanathan V, Zargar AH, Talwalkar PG, Wangoo SK, Maji D, Kumar GV, Sharma RK, Chafekar D, Mohan B, Bantwal G, Bansali A, Sahni JS. Protocol of an observation al study to evaluate diabetic nephropathy through detection of mucroalbuminuria in Indian patients. Indian J Endocrinol Metab. 2013 May;17(3):496-504.
    • Zubair Ahmed, Jamal Ahmad, Abida Malik, Mohammad Asim Siddiqui, Sibhash Kumar Wangnoo, Cathepsin-d, Adiponection, TNF-alpha, IL-6 and hsCRP plasma levesl in subjects with diabetic foot and possible correlation with clinical variables: a multicentric study. Ahmad J, Zubair M, Malik A, Siddiqui MA, Wangnoo SK. Foot (Ednib).2012 Sep;22(3):1949-9. EPup 2012 May 3.
    • Unnikrishnan AG, Wangnoo SK, Joshi SR, Banerjee S, Kumar A, Kalra S, channabasavaiah R, Shetty R.Physician perceptions and practices in management of diabetes in India: Results from the IMPROVE Control program. Indian K Endocrinol Metab. 2012 Dec;16(suppl 2):S428-9.
    • Jindal R, Ahmad A, Siddiqui MA, Wangnoo SK. What the future holds for gliptins. Indian J Endocrinol Metab.2012 Dec;16(suppl 2): S242-4.
    • Ahmad A, Siddiqui Ma, Goyal A, Wangnoo SK. BMJ Case Rep.2012 Jul 18:2012.
    • Mohan v, Unnikrishnan R, Thomas N, Bhansali A, Wangnoo SK, Thomas K. Pneumococcal inections and immunization in diabetic patients. J Postguard Med.2011 Jan-Mar;57(1):78-81.
    • M. Siddiqui, M. Gupta, V. KAul, S.K. Wangnoo . Improvement in Glycemic control daily injections in diabetes in pregnancy. Diabetes Technology and Therapeutics Volume 13, Number 2, 2011;P273-274.
    • Mohammad Siddiqui, Mukul Gupta, Subhash Wangnoo & Jamal Ahmad. Safety profile of Vidagliptin in clinical pratice: 2-year data from 2 Teritary hospitals. Endocine Abstracts (2011)25P128.
    • Mohammad Asim Siddiqui, Ayesha Ahmad, Mukul Gupta, Nitin Guptam Subhash Kumar Wangnoo. Prevalence of Abnormal Metabolic Parameters in Overweight Non-Diabetic children. Endocr Rev June 2011;32, P3-421.
    • Mukul Gupta, Mohammad Asim Siddiqui, Ayesha Ahmad, Mukul Gupta , Nitin Gupta, Subhash Kumar Wangnoo. Durability of Effects of Exenatide Treatment of Glycemic Control, Body Weight, hsCRP, Lipid Concentrations and Bone Mineral Density. Endocr Rev, Vol.32:P3-492.
    • Mohammad Asim Siddiqui, Mukul gupta, Nitin Gupta, Subhash Kumar Wangnoo. Improvements in Metabolic Parameters along with Glycemic Status in Newly Diagnosed Obese North Indian Type 2 Diabetes on Liraglutide Addition to Metfromin Monotherapy. Daibetes July 2011 60; A6092292 PO.
    • Mohammad Asim Siddiqui, SK Wangnoo. Metabolic Phenotype in brother's of women with polycystic ovarian syndrome. Endocrine Abstracts.P165(2010). Vol21.
    • M Gupta, MA Siddiqui, SK Wangnoo. Risk Awareness of Conversion of Gestational Diabetes Mellitus into Diabetes among women with Previous History of GDM and Treating General Practioners Endocrine Reviews, Supplement 1, June 2010, 31(3); S1443.
    • M.A. Siddiqui, M gupta, SK Wangnoo, J Ahmad, Clinical And Metabolic Heterogenity in Obese and Lean Women With Polycystic Ovarian Disease. Endocine Reviews, Supplement 1, June 2010, 31(3):S2108.
    • S.k.Wangnoo, M.A. Siddiqui, M. Gupta. Effect of Long-Acting Obstructive Sandostatin Analogs On Blood Glucose Profiles in Patient with Acromegaly. Endocine Reviews, Supplement 1, June 2010, 31(3):S2256.
    • S.K. Wangnoo, M.A. Siddiqui, M. gupta, M.S.Kanwar. Obstructive Sleep Apnoea and metabolic abnormalities in type 2 diabetes, Diabetologia (2010)53:(suppl I)S1-S556.
    • N Shamra , H. Dua, MA Siddiqui, M Gupta, SK Wangnoo. Prevalence of 25 Hydroxyvitamin D Deficiency in Newly Diagnosed Multiple Myeloma patients in a tertiary Care setting. Osteoporosis International (2010). Volume 21. Supplements 5.
    • Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S, Munjal YP; consensus Group. Consensus statement  for diagnosis of obesity, abdominal obesity and the metabolic syndorme for Asian Indians and recommendations for physicial activity, medical and surgical management. J Assoc Physician India.2009 Feb; 57:163-70.
    • Jadzinsky M, Pftitzner A, Paz-Pachoo E, XU Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in  patients with type 2 diabetes compared with either monotherpay: a randomized controlled trial. Diabetes obes Metab. 2009Jun;11(6):611-22.
    • Govalkar RM, Wangnoo SK. Localized genital kaposi sarcoma. ANN Saudi Med.1994 Nov;14(6):517-8. 36. Koul R, Saxena R, Wangnoo S. Myelomyopathy and throtoxicosis. J Assoc Physician India. 1989 Nov 37(11):721 Siddiqui MA, Wangnoo SK, Selective IgG subclass antibody response to insulin in diabetic receiving animal insulin replacement therapy. Int Arch Allergy Appl Immunol. 1989;89(1):49-53.
    Services
    Languages spoken

    English,Hindi

    Gender

    male

    Apollo Hospitals Delhi

    Indraprastha Apollo Hospitals, Sarita Vihar, Delhi-mathura Road, New Delhi - 110076. India Ph:011-26925858 011-29871090/1091, Delhi, New Delhi - 110076